EP2624698A4 - FURO[3,2-d]PYRIMIDINE COMPOUNDS - Google Patents

FURO[3,2-d]PYRIMIDINE COMPOUNDS

Info

Publication number: EP2624698A4
Authority: EP; European Patent Office
Prior art keywords: furo; pyrimidine compounds; pyrimidine; compounds
Prior art date: 2010-10-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP11831679.3A

Other languages

German (de)

French (fr)

Other versions

EP2624698A1 (en

Inventor

David J Calderwood

Noel S Wilson

Philip Cox

Michael Z Hoemann

Bruce Clapham

Kelly D Mullen

Anil Vasudevan

Clara I Villamil

Bin Li

Gagandeep Somal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AbbVie Inc

Original Assignee

AbbVie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-08

Filing date

2011-10-07

Publication date

2014-10-08

2011-10-07 Application filed by AbbVie Inc filed Critical AbbVie Inc

2013-08-14 Publication of EP2624698A1 publication Critical patent/EP2624698A1/en

2014-10-08 Publication of EP2624698A4 publication Critical patent/EP2624698A4/en

Status Withdrawn legal-status Critical Current

Links

JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical class C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Diabetes (AREA)
Oncology (AREA)
Immunology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)

EP11831679.3A 2010-10-08 2011-10-07 FURO[3,2-d]PYRIMIDINE COMPOUNDS Withdrawn EP2624698A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39115710P	2010-10-08	2010-10-08
US201161503368P	2011-06-30	2011-06-30
PCT/US2011/055366 WO2012048222A1 (en)	2010-10-08	2011-10-07	FURO[3,2-d]PYRIMIDINE COMPOUNDS

Publications (2)

Publication Number	Publication Date
EP2624698A1 EP2624698A1 (en)	2013-08-14
EP2624698A4 true EP2624698A4 (en)	2014-10-08

Family

ID=45928140

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP11831679.3A Withdrawn EP2624698A4 (en)	2010-10-08	2011-10-07	FURO[3,2-d]PYRIMIDINE COMPOUNDS

Country Status (23)

Country	Link
US (1)	US8551981B2 (en)
EP (1)	EP2624698A4 (en)
JP (1)	JP2013539762A (en)
KR (1)	KR20140005882A (en)
CN (1)	CN103442568A (en)
AR (1)	AR083358A1 (en)
AU (1)	AU2011311867A1 (en)
BR (1)	BR112013008240A2 (en)
CA (1)	CA2813437A1 (en)
CL (1)	CL2013000933A1 (en)
CO (1)	CO6731080A2 (en)
CR (1)	CR20130206A (en)
EC (1)	ECSP13012554A (en)
GT (1)	GT201300091A (en)
IL (1)	IL225622A0 (en)
MX (1)	MX2013003913A (en)
PE (1)	PE20140245A1 (en)
PH (1)	PH12013500661A1 (en)
RU (1)	RU2013120966A (en)
SG (1)	SG189837A1 (en)
TW (1)	TW201219398A (en)
UY (1)	UY33659A (en)
WO (1)	WO2012048222A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2011105768A (en) *	2008-08-01	2012-09-10	Биокрист Фармасьютикалз, Инк. (Us)	PIPERIDINE DERIVATIVES AS JAKЗ INHIBITORS
TW201204733A (en) *	2010-06-25	2012-02-01	Kowa Co	Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
WO2013019966A1 (en) *	2011-08-04	2013-02-07	Allergan, Inc.	Aromatic bycyclic derivatives as cxcr4 receptor modulators
US9879004B2 (en)	2013-02-07	2018-01-30	Merck Patent Gmbh	Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4
US9447025B2 (en)	2013-03-14	2016-09-20	Kalyra Pharmaceuticals, Inc.	Bicyclic analgesic compounds
UA119247C2 (en)	2013-09-06	2019-05-27	РОЙВЕНТ САЙЕНСИЗ ҐмбГ	Spirocyclic compounds as tryptophan hydroxylase inhibitors
RU2650512C2 (en)	2013-09-18	2018-04-16	Бейджин Ханми Фармасьютикал Ко., Лтд.	Compounding, which inhibites activity of btk and/or jak3 kinases
CN104903312B (en) *	2013-10-07	2019-01-29	卡德门企业有限公司	RHO kinase inhibitor
US10189780B2 (en)	2013-12-12	2019-01-29	Zeno Royalties & Milestones, LLC	Bicyclic alkyl compounds and synthesis
WO2015096035A1 (en) *	2013-12-24	2015-07-02	Merck Sharp & Dohme Corp.	Inhibitors of renal outer medullary potassium channel
CN106232567B (en)	2014-03-07	2021-11-02	里科瑞尔姆Ip控股有限责任公司	Propylane Derivatives and Synthesis
GB201410816D0 (en) *	2014-06-17	2014-07-30	Ucb Biopharma Sprl And Katholieke Universiteit Leuven	Therapeutic agents
CN106999451B (en)	2014-09-17	2021-04-02	里科瑞尔姆Ip控股有限责任公司	bicyclic compounds
CN105566329B (en) *	2014-11-07	2019-02-12	温州医科大学	A pyrazole[5,6-d]pyrimidine EGFR inhibitor and its antitumor activity
WO2016115272A1 (en) *	2015-01-13	2016-07-21	Vanderbilt University	Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9611201B2 (en)	2015-03-05	2017-04-04	Karos Pharmaceuticals, Inc.	Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN107531725B (en) *	2015-08-13	2021-03-19	北京韩美药品有限公司	IRAK4 inhibitors and their applications
CN105664178B (en) *	2015-09-24	2019-08-20	洪健	SYK is as the application of liver fibrosis/hardening treating target spot
US20190060257A1 (en) *	2016-03-16	2019-02-28	Zeno Royalties & Milestones, LLC	Analgesic compounds
EA201990523A1 (en)	2016-10-03	2019-10-31		NEW SELECTIVE JAK1 INHIBITORS AND THEIR APPLICATION
EP3562828B1 (en)	2016-12-28	2026-03-18	Dart Neuroscience LLC	Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
CN106841420A (en) *	2016-12-30	2017-06-13	广州中大南沙科技创新产业园有限公司	A kind of method that LC MS/MS determine Ly 7u concentration in rat plasma
EP3628043A4 (en)	2017-05-15	2021-04-28	Recurium IP Holdings, LLC	Analgesic compounds
MX2020005447A (en)	2017-11-27	2020-12-03	Dart Neuroscience Llc	Substituted furanopyrimidine compounds as pde1 inhibitors.
WO2020113182A1 (en) *	2018-11-30	2020-06-04	Celularity, Inc.	Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
UA130579C2 (en)	2019-03-05	2026-03-25	Інсайт Корпорейшн	Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
WO2020235902A1 (en) *	2019-05-17	2020-11-26	주식회사 보로노이	Heterocycle-fused pyrimidine derivative and use thereof
PH12022551379A1 (en)	2019-12-06	2023-05-03	Vertex Pharma	Substituted tetrahydrofurans as modulators of sodium channels
US12486274B2 (en)	2020-01-13	2025-12-02	Verge Analytics, Inc.	Substituted pyrazolo-pyrimidines and uses thereof
WO2021183439A1 (en) *	2020-03-09	2021-09-16	Verge Analytics, Inc.	Substituted furo[3,2-d]pyrimidines and uses thereof
CN114835687B (en) *	2021-04-02	2023-09-05	北京华森英诺生物科技有限公司	AhR inhibitors
WO2022216098A1 (en) *	2021-04-08	2022-10-13	주식회사 스탠다임	Novel lrrk2 inhibitor
CN113121537B (en) *	2021-04-13	2022-11-08	南通药明康德医药科技有限公司	Synthesis method of 2, 8-diazaspiro [4.5] decane-8-tert-butyl formate
SI4347031T1 (en)	2021-06-04	2026-01-30	Vertex Pharmaceuticals Incorporated	N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CN114105887B (en) *	2021-09-16	2023-12-01	沈阳药科大学	Aminopyrimidine derivative and preparation method and application thereof
US20260027118A1 (en) *	2022-05-12	2026-01-29	Skyhawk Therapeutics, Inc.	Compositions useful for modulating splicing
EP4547660A1 (en) *	2022-06-29	2025-05-07	Alcon Inc.	Azetidinyl pyrimidines and uses thereof as jak inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008013527A (en) *	2006-07-10	2008-01-24	Sankyo Co Ltd	THIENO[3,2-d]PYRIMIDINE-2,4-DIAMINE DERIVATIVE
WO2011162515A2 (en) *	2010-06-23	2011-12-29	Hanmi Holdings Co. , Ltd.	Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5877178A (en)	1991-04-08	1999-03-02	Duquesne University Of The Holy Ghost	Pyrimidine derivatives and methods of making and using these derivatives
SV2002000205A (en)	1999-11-01	2002-06-07	Lilly Co Eli	PHARMACEUTICAL COMPOUNDS REF. X-01095
GB0100620D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical cokpounds V
EP1465900B1 (en) *	2002-01-10	2008-05-14	Bayer HealthCare AG	Rho-kinase inhibitors
US20030199525A1 (en)	2002-03-21	2003-10-23	Hirst Gavin C.	Kinase inhibitors
US20050026944A1 (en) *	2003-07-24	2005-02-03	Patrick Betschmann	Thienopyridine and furopyridine kinase inhibitors
EA200600372A1 (en)	2003-09-05	2006-08-25	Ньюроджин Корпорейшн	CONDENSED WITH PYRIDINE HETEROARIL, PIRASINS AND PyRMIDINES AS LIGANDS OF THE CORTICOTROPIN-REALIZING FACTOR RECEPTOR (CRF 1)
BRPI0414238A (en)	2003-09-09	2006-10-31	Ono Pharmaceutical Co	CRF antagonists and heterobicyclic compounds
US20050153989A1 (en)	2004-01-13	2005-07-14	Ambit Biosciences Corporation	Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
GB0412986D0 (en) *	2004-06-10	2004-07-14	Xention Discovery Ltd	Compounds
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
CA2602533A1 (en)	2005-03-29	2006-10-05	Biocryst Pharmaceuticals, Inc.	Use of c-nucleoside analogs for treatment of hepatitis c related viral infections
WO2006128172A2 (en)	2005-05-26	2006-11-30	Synta Pharmaceuticals Corp.	Method for treating b cell regulated autoimmune disorders
WO2006128129A2 (en)	2005-05-26	2006-11-30	Synta Pharmaceuticals Corp.	Method for treating cancer
EP2003131A4 (en)	2006-04-04	2009-12-16	Taisho Pharmaceutical Co Ltd	aminopyrrolidine
PL2041139T3 (en) *	2006-04-26	2012-05-31	Hoffmann La Roche	Pharmaceutical compounds
TW200951136A (en) *	2008-03-17	2009-12-16	Palau Pharma Sa	Furo[3,2-d]pyrimidine derivatives
AU2009233964B2 (en) *	2008-04-07	2012-06-07	Irm Llc	Compounds and compositions as protein kinase inhibitors
RU2012130929A (en)	2009-12-23	2014-01-27	Байокрист Фармасьютикалз, Инк.	HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS

2011
- 2011-10-07 RU RU2013120966/04A patent/RU2013120966A/en not_active Application Discontinuation
- 2011-10-07 BR BR112013008240A patent/BR112013008240A2/en not_active IP Right Cessation
- 2011-10-07 WO PCT/US2011/055366 patent/WO2012048222A1/en not_active Ceased
- 2011-10-07 US US13/268,387 patent/US8551981B2/en active Active
- 2011-10-07 PE PE2013000803A patent/PE20140245A1/en not_active Application Discontinuation
- 2011-10-07 TW TW100136629A patent/TW201219398A/en unknown
- 2011-10-07 CN CN2011800573262A patent/CN103442568A/en active Pending
- 2011-10-07 UY UY0001033659A patent/UY33659A/en unknown
- 2011-10-07 MX MX2013003913A patent/MX2013003913A/en not_active Application Discontinuation
- 2011-10-07 CA CA2813437A patent/CA2813437A1/en not_active Abandoned
- 2011-10-07 SG SG2013025333A patent/SG189837A1/en unknown
- 2011-10-07 AU AU2011311867A patent/AU2011311867A1/en not_active Abandoned
- 2011-10-07 KR KR1020137011942A patent/KR20140005882A/en not_active Withdrawn
- 2011-10-07 PH PH1/2013/500661A patent/PH12013500661A1/en unknown
- 2011-10-07 EP EP11831679.3A patent/EP2624698A4/en not_active Withdrawn
- 2011-10-07 JP JP2013532974A patent/JP2013539762A/en active Pending
- 2011-10-11 AR ARP110103722A patent/AR083358A1/en not_active Application Discontinuation
2013
- 2013-04-05 CL CL2013000933A patent/CL2013000933A1/en unknown
- 2013-04-05 GT GT201300091A patent/GT201300091A/en unknown
- 2013-04-07 IL IL225622A patent/IL225622A0/en unknown
- 2013-04-16 EC ECSP13012554 patent/ECSP13012554A/en unknown
- 2013-05-08 CO CO13115325A patent/CO6731080A2/en not_active Application Discontinuation
- 2013-05-08 CR CR20130206A patent/CR20130206A/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008013527A (en) *	2006-07-10	2008-01-24	Sankyo Co Ltd	THIENO[3,2-d]PYRIMIDINE-2,4-DIAMINE DERIVATIVE
WO2011162515A2 (en) *	2010-06-23	2011-12-29	Hanmi Holdings Co. , Ltd.	Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012048222A1 *

Also Published As

Publication number	Publication date
UY33659A (en)	2012-04-30
US8551981B2 (en)	2013-10-08
PE20140245A1 (en)	2014-03-30
AR083358A1 (en)	2013-02-21
CL2013000933A1 (en)	2014-04-25
WO2012048222A1 (en)	2012-04-12
MX2013003913A (en)	2013-09-26
CA2813437A1 (en)	2012-04-12
IL225622A0 (en)	2013-06-27
BR112013008240A2 (en)	2017-12-12
CO6731080A2 (en)	2013-08-15
GT201300091A (en)	2014-07-11
AU2011311867A1 (en)	2013-04-18
RU2013120966A (en)	2014-11-20
KR20140005882A (en)	2014-01-15
US20120122846A1 (en)	2012-05-17
CR20130206A (en)	2013-08-07
SG189837A1 (en)	2013-06-28
ECSP13012554A (en)	2013-06-28
CN103442568A (en)	2013-12-11
JP2013539762A (en)	2013-10-28
EP2624698A1 (en)	2013-08-14
PH12013500661A1 (en)	2017-08-23
TW201219398A (en)	2012-05-16

Legal Events

Date	Code	Title	Description
2013-07-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-08-14	17P	Request for examination filed	Effective date: 20130508
2013-08-14	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2013-08-14	AX	Request for extension of the european patent	Extension state: BA ME
2014-04-17	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1187783 Country of ref document: HK
2014-10-08	A4	Supplementary search report drawn up and despatched	Effective date: 20140904
2014-10-08	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/519 20060101ALI20140829BHEP Ipc: C07D 491/04 20060101ALI20140829BHEP Ipc: A61P 25/00 20060101ALI20140829BHEP Ipc: A61P 9/00 20060101ALI20140829BHEP Ipc: A61P 35/00 20060101ALI20140829BHEP Ipc: C07D 239/42 20060101AFI20140829BHEP
2015-09-09	17Q	First examination report despatched	Effective date: 20150810
2016-04-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2016-05-25	18D	Application deemed to be withdrawn	Effective date: 20151222
2020-05-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1187783 Country of ref document: HK

Publication	Publication Date	Title
IL266285A (en)	2019-06-30	Methods for the preparation of thieno [3,2-d] pyrimidine compounds
SG11201401342VA (en)	2014-09-26	5,7-substituted-imidazo[1,2-c]pyrimidines
ZA201202718B (en)	2012-12-27	Pyrrolo[2,3-d]pyrimidine compounds
IL225622A0 (en)	2013-06-27	Furo[3, 2-di]pyrimidine compounds
AP3709A (en)	2016-05-31	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
IL234485A (en)	2017-02-28	Imidazo [1,2-b] pyridazine-based compounds
ZA201209029B (en)	2014-02-26	Novel pyrimidine derivatives
IL226004A0 (en)	2013-06-27	Novel antiviral compounds
PH12013501402A1 (en)	2013-08-28	Mesoionic Pyrido [1,2 -A] Pyrimidine Pesticides
GB201012105D0 (en)	2010-09-01	Novel pyrimidine compounds
EP2633062A4 (en)	2014-08-13	Biotin derivatives
EP2582704A4 (en)	2014-04-02	Asenapine maleate
ZA201406323B (en)	2016-08-31	Triazolo[4,5-d]pyrimidine derivatives
IL229993A (en)	2015-10-29	5-substituted-8-alkoxy [1,2,4] triazolo[1,5-c] pyrimidin-2-amines
ZA201208616B (en)	2015-08-26	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
IL232717B (en)	2018-08-30	3-cyanoaryl-1h-pyrrolo[2,3-b]pyridine derivatives
PL2694513T3 (en)	2015-06-30	Pyrazolo pyrimidine derivatives
ZA201105528B (en)	2012-09-26	2-morpholino-pyrido[3,2-d]pyrimidines
HK1187783A (en)	2014-04-17	Furo[3,2-d]pyrimidine compounds
AU2010100755A4 (en)	2010-08-12	Haloumi Shapes
AU2013204145B2 (en)	2016-03-31	Pure erlotinib
HK1196363A (en)	2014-12-12	5,7-substituted-imidazo[1,2-c]pyrimidines
AU4366P (en)	2011-12-21	PFS100 Scaevola humilis
HK1189883A (en)	2014-06-20	Novel antiviral compounds
AU2011903302A0 (en)	2011-09-08	Utility vest